Latest News

Post hoc phase 3 analyses linked centanafadine to improved executive function and emotional regulation in adults with ADHD.

ACS updated colorectal cancer screening guidance, reaffirming screening at age 45 and adding newer stool-based and blood-based options.

Kohli discusses the FDA approval of baxdrostat (Baxfendy), the first aldosterone synthase inhibitor for adults with uncontrolled hypertension.

A validated AI phenotyping tool identified chronic long COVID burden missed by ICD surveillance in nearly 460,000 COVID-19 patients.

Elunetirom received FDA Fast Track designation as an adjunctive therapy for bipolar depression, with phase 2 AMPLIFY-BD data expected in 2026.

VERVE-102 reduced PCSK9 and LDL-C after one infusion in early Heart-2 data for patients needing additional lipid lowering.

FDA approved bulevirtide-gmod (Hepcludex; Gilead Sciences) for adults with chronic HDV infection without cirrhosis or with compensated cirrhosis, based on phase 3 data.

Orforglipron reduced body weight versus placebo in adults aged 65 years or older with obesity or overweight in ATTAIN-1 and ATTAIN-2.